25 XP   0   0   10

Bafna Pharmaceuticals Limited
Buy, Hold or Sell?

Let's analyse Bafna Pharmaceuticals Limited together

PenkeI guess you are interested in Bafna Pharmaceuticals Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Bafna Pharmaceuticals Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Bafna Pharmaceuticals Limited

I send you an email if I find something interesting about Bafna Pharmaceuticals Limited.

Quick analysis of Bafna Pharmaceuticals Limited (30 sec.)










What can you expect buying and holding a share of Bafna Pharmaceuticals Limited? (30 sec.)

How much money do you get?

How much money do you get?
INR0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
INR31.05
Expected worth in 1 year
INR48.93
How sure are you?
60.0%

+ What do you gain per year?

Total Gains per Share
INR17.88
Return On Investment
20.7%

For what price can you sell your share?

Current Price per Share
INR86.50
Expected price per share
INR75.90 - INR92.70
How sure are you?
50%

1. Valuation of Bafna Pharmaceuticals Limited (5 min.)




Live pricePrice per Share (EOD)

INR86.50

Intrinsic Value Per Share

INR-96.56 - INR178.59

Total Value Per Share

INR-65.51 - INR209.64

2. Growth of Bafna Pharmaceuticals Limited (5 min.)




Is Bafna Pharmaceuticals Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$8.8m$7.5m$1.2m14.4%

How much money is Bafna Pharmaceuticals Limited making?

Current yearPrevious yearGrowGrow %
Making money$1.3m$625.9k$734.6k54.0%
Net Profit Margin9.8%6.1%--

How much money comes from the company's main activities?

3. Financial Health of Bafna Pharmaceuticals Limited (5 min.)




What can you expect buying and holding a share of Bafna Pharmaceuticals Limited? (5 min.)

Welcome investor! Bafna Pharmaceuticals Limited's management wants to use your money to grow the business. In return you get a share of Bafna Pharmaceuticals Limited.

What can you expect buying and holding a share of Bafna Pharmaceuticals Limited?

First you should know what it really means to hold a share of Bafna Pharmaceuticals Limited. And how you can make/lose money.

Speculation

The Price per Share of Bafna Pharmaceuticals Limited is INR86.50. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Bafna Pharmaceuticals Limited.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Bafna Pharmaceuticals Limited, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR31.05. Based on the TTM, the Book Value Change Per Share is INR4.47 per quarter. Based on the YOY, the Book Value Change Per Share is INR2.58 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Bafna Pharmaceuticals Limited.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps0.060.1%0.060.1%0.030.0%-0.020.0%-0.030.0%
Usd Book Value Change Per Share0.050.1%0.050.1%0.030.0%0.040.0%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.050.1%0.050.1%0.030.0%0.040.0%0.000.0%
Usd Price Per Share0.98-0.98-1.52-0.89-0.60-
Price to Earnings Ratio17.11-17.11-58.16-25.72-15.62-
Price-to-Total Gains Ratio18.34-18.34-49.04-25.09-15.46-
Price to Book Ratio2.64-2.64-4.76-2.99-2.12-
Price-to-Total Gains Ratio18.34-18.34-49.04-25.09-15.46-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.038
Number of shares963
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.050.04
Usd Total Gains Per Share0.050.04
Gains per Quarter (963 shares)51.6535.42
Gains per Year (963 shares)206.62141.67
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
102071970142132
204134040283274
306206110425416
408268180567558
50103310250708700
60124012320850842
70144614390992984
8016531646011331126
9018601853012751268
10020662060014171410

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%3.02.00.060.0%5.05.00.050.0%12.05.00.070.6%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%6.04.00.060.0%13.04.00.076.5%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.017.00.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%6.04.00.060.0%13.04.00.076.5%

Fundamentals of Bafna Pharmaceuticals Limited

About Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company provides delayed and sustained release, chewable, and orally disintegrating tablets. It also exports its products. The company was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited operates as a subsidiary of SRJR Lifesciences LLP.

Fundamental data was last updated by Penke on 2024-04-09 10:55:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Bafna Pharmaceuticals Limited.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Bafna Pharmaceuticals Limited earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare Bafna Pharmaceuticals Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 9.8% means that ₹0.10 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Bafna Pharmaceuticals Limited:

  • The MRQ is 9.8%. The company is making a profit. +1
  • The TTM is 9.8%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ9.8%TTM9.8%0.0%
TTM9.8%YOY6.1%+3.7%
TTM9.8%5Y-15.5%+25.4%
5Y-15.5%10Y-15.2%-0.3%
1.1.2. Return on Assets

Shows how efficient Bafna Pharmaceuticals Limited is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Bafna Pharmaceuticals Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • 8.7% Return on Assets means that Bafna Pharmaceuticals Limited generated ₹0.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Bafna Pharmaceuticals Limited:

  • The MRQ is 8.7%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 8.7%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ8.7%TTM8.7%0.0%
TTM8.7%YOY5.8%+3.0%
TTM8.7%5Y-5.8%+14.6%
5Y-5.8%10Y-5.6%-0.3%
1.1.3. Return on Equity

Shows how efficient Bafna Pharmaceuticals Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Bafna Pharmaceuticals Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • 15.4% Return on Equity means Bafna Pharmaceuticals Limited generated ₹0.15 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Bafna Pharmaceuticals Limited:

  • The MRQ is 15.4%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 15.4%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ15.4%TTM15.4%0.0%
TTM15.4%YOY8.3%+7.1%
TTM15.4%5Y-22.7%+38.1%
5Y-22.7%10Y-21.6%-1.1%

1.2. Operating Efficiency of Bafna Pharmaceuticals Limited.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Bafna Pharmaceuticals Limited is operating .

  • Measures how much profit Bafna Pharmaceuticals Limited makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Bafna Pharmaceuticals Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 11.8% means the company generated ₹0.12  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Bafna Pharmaceuticals Limited:

  • The MRQ is 11.8%. The company is operating less efficient.
  • The TTM is 11.8%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ11.8%TTM11.8%0.0%
TTM11.8%YOY9.2%+2.6%
TTM11.8%5Y1.9%+10.0%
5Y1.9%10Y-0.4%+2.3%
1.2.2. Operating Ratio

Measures how efficient Bafna Pharmaceuticals Limited is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.91 means that the operating costs are ₹0.91 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Bafna Pharmaceuticals Limited:

  • The MRQ is 0.910. The company is less efficient in keeping operating costs low.
  • The TTM is 0.910. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.910TTM0.9100.000
TTM0.910YOY0.924-0.014
TTM0.9105Y0.992-0.082
5Y0.99210Y1.052-0.060

1.3. Liquidity of Bafna Pharmaceuticals Limited.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Bafna Pharmaceuticals Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.88 means the company has ₹1.88 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Bafna Pharmaceuticals Limited:

  • The MRQ is 1.879. The company is able to pay all its short-term debts. +1
  • The TTM is 1.879. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.879TTM1.8790.000
TTM1.879YOY3.136-1.257
TTM1.8795Y1.971-0.092
5Y1.97110Y1.563+0.408
1.3.2. Quick Ratio

Measures if Bafna Pharmaceuticals Limited is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Bafna Pharmaceuticals Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.06 means the company can pay off ₹1.06 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Bafna Pharmaceuticals Limited:

  • The MRQ is 1.065. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 1.065. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.065TTM1.0650.000
TTM1.065YOY0.912+0.152
TTM1.0655Y0.852+0.212
5Y0.85210Y0.555+0.297

1.4. Solvency of Bafna Pharmaceuticals Limited.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Bafna Pharmaceuticals Limited assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Bafna Pharmaceuticals Limited to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.43 means that Bafna Pharmaceuticals Limited assets are financed with 43.3% credit (debt) and the remaining percentage (100% - 43.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Bafna Pharmaceuticals Limited:

  • The MRQ is 0.433. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.433. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.433TTM0.4330.000
TTM0.433YOY0.303+0.130
TTM0.4335Y0.441-0.008
5Y0.44110Y0.574-0.133
1.4.2. Debt to Equity Ratio

Measures if Bafna Pharmaceuticals Limited is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Bafna Pharmaceuticals Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 76.4% means that company has ₹0.76 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Bafna Pharmaceuticals Limited:

  • The MRQ is 0.764. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.764. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.764TTM0.7640.000
TTM0.764YOY0.435+0.329
TTM0.7645Y1.479-0.715
5Y1.47910Y1.977-0.498

2. Market Valuation of Bafna Pharmaceuticals Limited

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Bafna Pharmaceuticals Limited generates.

  • Above 15 is considered overpriced but always compare Bafna Pharmaceuticals Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 17.11 means the investor is paying ₹17.11 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Bafna Pharmaceuticals Limited:

  • The EOD is 18.048. Based on the earnings, the company is fair priced.
  • The MRQ is 17.109. Based on the earnings, the company is fair priced.
  • The TTM is 17.109. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD18.048MRQ17.109+0.939
MRQ17.109TTM17.1090.000
TTM17.109YOY58.164-41.055
TTM17.1095Y25.724-8.615
5Y25.72410Y15.616+10.107
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Bafna Pharmaceuticals Limited:

  • The EOD is -62.652. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -59.392. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -59.392. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-62.652MRQ-59.392-3.259
MRQ-59.392TTM-59.3920.000
TTM-59.392YOY610.571-669.963
TTM-59.3925Y104.606-163.998
5Y104.60610Y20.318+84.288
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Bafna Pharmaceuticals Limited is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 2.64 means the investor is paying ₹2.64 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Bafna Pharmaceuticals Limited:

  • The EOD is 2.786. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.641. Based on the equity, the company is underpriced. +1
  • The TTM is 2.641. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.786MRQ2.641+0.145
MRQ2.641TTM2.6410.000
TTM2.641YOY4.765-2.124
TTM2.6415Y2.992-0.351
5Y2.99210Y2.118+0.874
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Bafna Pharmaceuticals Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--4.4704.4700%2.583+73%3.065+46%0.218+1953%
Book Value Per Share--31.05131.0510%26.581+17%22.248+40%22.933+35%
Current Ratio--1.8791.8790%3.136-40%1.971-5%1.563+20%
Debt To Asset Ratio--0.4330.4330%0.303+43%0.441-2%0.574-25%
Debt To Equity Ratio--0.7640.7640%0.435+76%1.479-48%1.977-61%
Dividend Per Share----0%-0%-0%-0%
Eps--4.7934.7930%2.177+120%-1.840+138%-2.707+156%
Free Cash Flow Per Share---1.381-1.3810%0.207-766%-5.101+269%-3.115+126%
Free Cash Flow To Equity Per Share--2.9212.9210%-1.578+154%-4.073+239%-7.205+347%
Gross Profit Margin--0.9500.9500%0.551+72%0.890+7%0.9520%
Intrinsic Value_10Y_max--178.590--------
Intrinsic Value_10Y_min---96.560--------
Intrinsic Value_1Y_max--1.418--------
Intrinsic Value_1Y_min---6.319--------
Intrinsic Value_3Y_max--16.819--------
Intrinsic Value_3Y_min---22.005--------
Intrinsic Value_5Y_max--47.361--------
Intrinsic Value_5Y_min---40.882--------
Market Cap2046269950.000+5%1939816600.0001939816600.0000%2996070395.000-35%1746072532.700+11%1191095219.850+63%
Net Profit Margin--0.0980.0980%0.061+60%-0.155+258%-0.152+254%
Operating Margin--0.1180.1180%0.092+29%0.019+531%-0.004+103%
Operating Ratio--0.9100.9100%0.924-2%0.992-8%1.052-14%
Pb Ratio2.786+5%2.6412.6410%4.765-45%2.992-12%2.118+25%
Pe Ratio18.048+5%17.10917.1090%58.164-71%25.724-33%15.616+10%
Price Per Share86.500+5%82.00082.0000%126.650-35%73.810+11%50.350+63%
Price To Free Cash Flow Ratio-62.652-5%-59.392-59.3920%610.571-110%104.606-157%20.318-392%
Price To Total Gains Ratio19.351+5%18.34518.3450%49.041-63%25.086-27%15.457+19%
Quick Ratio--1.0651.0650%0.912+17%0.852+25%0.555+92%
Return On Assets--0.0870.0870%0.058+51%-0.058+167%-0.056+164%
Return On Equity--0.1540.1540%0.083+86%-0.227+247%-0.216+240%
Total Gains Per Share--4.4704.4700%2.583+73%3.065+46%0.218+1953%
Usd Book Value--8814552.0008814552.0000%7545636.000+17%6315684.000+40%6510000.912+35%
Usd Book Value Change Per Share--0.0540.0540%0.031+73%0.037+46%0.003+1953%
Usd Book Value Per Share--0.3730.3730%0.319+17%0.267+40%0.275+35%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.0580.0580%0.026+120%-0.022+138%-0.032+156%
Usd Free Cash Flow---391932.000-391932.0000%58884.000-766%-1448083.200+269%-884143.956+126%
Usd Free Cash Flow Per Share---0.017-0.0170%0.002-766%-0.061+269%-0.037+126%
Usd Free Cash Flow To Equity Per Share--0.0350.0350%-0.019+154%-0.049+239%-0.086+347%
Usd Market Cap24555239.400+5%23277799.20023277799.2000%35952844.740-35%20952870.392+11%14293142.638+63%
Usd Price Per Share1.038+5%0.9840.9840%1.520-35%0.886+11%0.604+63%
Usd Profit--1360560.0001360560.0000%625956.000+117%-509248.800+137%-761855.052+156%
Usd Revenue--13841988.00013841988.0000%10216848.000+35%8580950.400+61%10056054.864+38%
Usd Total Gains Per Share--0.0540.0540%0.031+73%0.037+46%0.003+1953%
 EOD+5 -3MRQTTM+0 -0YOY+24 -105Y+31 -310Y+30 -4

3.2. Fundamental Score

Let's check the fundamental score of Bafna Pharmaceuticals Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1518.048
Price to Book Ratio (EOD)Between0-12.786
Net Profit Margin (MRQ)Greater than00.098
Operating Margin (MRQ)Greater than00.118
Quick Ratio (MRQ)Greater than11.065
Current Ratio (MRQ)Greater than11.879
Debt to Asset Ratio (MRQ)Less than10.433
Debt to Equity Ratio (MRQ)Less than10.764
Return on Equity (MRQ)Greater than0.150.154
Return on Assets (MRQ)Greater than0.050.087
Total8/10 (80.0%)

3.3. Technical Score

Let's check the technical score of Bafna Pharmaceuticals Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.370
Ma 20Greater thanMa 5085.478
Ma 50Greater thanMa 10086.901
Ma 100Greater thanMa 20092.595
OpenGreater thanClose88.850
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets1,295,832
Total Liabilities561,286
Total Stockholder Equity734,546
 As reported
Total Liabilities 561,286
Total Stockholder Equity+ 734,546
Total Assets = 1,295,832

Assets

Total Assets1,295,832
Total Current Assets873,117
Long-term Assets422,715
Total Current Assets
Cash And Cash Equivalents 78,100
Net Receivables 416,773
Inventory 222,196
Other Current Assets 156,048
Total Current Assets  (as reported)873,117
Total Current Assets  (calculated)873,117
+/-0
Long-term Assets
Property Plant Equipment 402,297
Intangible Assets 15,000
Long-term Assets Other 5,418
Long-term Assets  (as reported)422,715
Long-term Assets  (calculated)422,715
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities464,763
Long-term Liabilities96,523
Total Stockholder Equity734,546
Total Current Liabilities
Short-term Debt 144,906
Short Long Term Debt 144,906
Accounts payable 284,607
Other Current Liabilities 21,200
Total Current Liabilities  (as reported)464,763
Total Current Liabilities  (calculated)595,619
+/- 130,856
Long-term Liabilities
Long term Debt 84,333
Long-term Liabilities  (as reported)96,523
Long-term Liabilities  (calculated)84,333
+/- 12,190
Total Stockholder Equity
Common Stock236,563
Retained Earnings -544,831
Accumulated Other Comprehensive Income 289,049
Other Stockholders Equity 753,765
Total Stockholder Equity (as reported)734,546
Total Stockholder Equity (calculated)734,546
+/-0
Other
Capital Stock236,563
Cash and Short Term Investments 78,100
Common Stock Shares Outstanding 23,656
Current Deferred Revenue14,050
Liabilities and Stockholders Equity 1,295,832
Net Debt 151,139
Net Invested Capital 963,785
Net Working Capital 408,354
Property Plant and Equipment Gross 402,297
Short Long Term Debt Total 229,239



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-312013-03-312012-03-312011-03-312010-03-312009-03-312008-03-312007-03-31
> Total Assets 
540,088
511,273
778,291
841,280
1,356,213
2,189,397
2,605,853
2,358,245
1,998,292
1,925,247
1,783,079
1,383,624
1,194,721
713,126
864,659
902,444
1,295,832
1,295,832902,444864,659713,1261,194,7211,383,6241,783,0791,925,2471,998,2922,358,2452,605,8532,189,3971,356,213841,280778,291511,273540,088
   > Total Current Assets 
284,537
187,706
389,074
440,982
875,746
1,366,185
1,785,546
1,564,770
1,270,878
1,223,013
1,122,189
487,391
484,690
360,957
496,682
513,988
873,117
873,117513,988496,682360,957484,690487,3911,122,1891,223,0131,270,8781,564,7701,785,5461,366,185875,746440,982389,074187,706284,537
       Cash And Cash Equivalents 
17,669
11,910
20,319
18,412
117,800
24,648
210,709
28,062
27,702
27,138
26,579
5,011
1,395
81,853
7,476
194
78,100
78,1001947,47681,8531,3955,01126,57927,13827,70228,062210,70924,648117,80018,41220,31911,91017,669
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
565,449
286,660
389,329
134,570
106,156
149,331
416,773
416,773149,331106,156134,570389,329286,660565,4490000000000
       Inventory 
65,611
53,712
46,567
93,382
147,476
239,190
222,127
274,020
161,228
163,799
167,399
106,742
92,823
114,116
154,434
202,805
222,196
222,196202,805154,434114,11692,823106,742167,399163,799161,228274,020222,127239,190147,47693,38246,56753,71265,611
       Other Current Assets 
201,256
122,084
322,188
329,188
610,470
1,102,347
1,352,710
1,262,689
1,081,948
1,032,075
928,210
375,638
1,143
164,988
228,616
161,658
156,048
156,048161,658228,616164,9881,143375,638928,2101,032,0751,081,9481,262,6891,352,7101,102,347610,470329,188322,188122,084201,256
   > Long-term Assets 
255,551
323,566
389,217
400,299
480,466
823,213
820,307
793,475
727,414
702,234
660,890
896,233
710,031
352,169
367,977
388,456
422,715
422,715388,456367,977352,169710,031896,233660,890702,234727,414793,475820,307823,213480,466400,299389,217323,566255,551
       Property Plant Equipment 
227,963
232,638
368,949
385,217
470,412
557,803
547,944
533,517
545,257
525,709
485,750
448,603
370,190
351,813
367,979
388,459
402,297
402,297388,459367,979351,813370,190448,603485,750525,709545,257533,517547,944557,803470,412385,217368,949232,638227,963
       Goodwill 
0
0
0
0
0
358
0
0
0
0
0
358
358
358
0
0
0
0003583583580000035800000
       Intangible Assets 
0
0
0
0
0
204,242
0
0
0
0
0
0
0
0
0
15,000
15,000
15,00015,000000000000204,24200000
       Long-term Assets Other 
27,588
90,928
20,268
15,081
10,054
60,810
272,363
259,958
182,157
176,526
175,140
447,272
339,483
-2
-2
-3
5,418
5,418-3-2-2339,483447,272175,140176,526182,157259,958272,36360,81010,05415,08120,26890,92827,588
> Total Liabilities 
448,698
392,723
393,058
431,234
814,325
1,543,228
1,922,815
1,660,763
1,271,164
1,349,532
1,361,962
1,011,600
1,006,200
201,172
296,948
273,641
561,286
561,286273,641296,948201,1721,006,2001,011,6001,361,9621,349,5321,271,1641,660,7631,922,8151,543,228814,325431,234393,058392,723448,698
   > Total Current Liabilities 
276,279
143,631
141,750
111,212
275,674
1,227,422
1,600,099
1,354,291
1,110,861
950,450
814,717
598,468
708,209
170,996
243,087
163,898
464,763
464,763163,898243,087170,996708,209598,468814,717950,4501,110,8611,354,2911,600,0991,227,422275,674111,212141,750143,631276,279
       Short-term Debt 
0
0
0
0
0
0
749,864
852,736
570,131
453,079
433,729
232,910
232,397
-25,098
105,000
11,508
144,906
144,90611,508105,000-25,098232,397232,910433,729453,079570,131852,736749,864000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
433,729
232,910
232,397
0
105,000
11,508
144,906
144,90611,508105,0000232,397232,910433,7290000000000
       Accounts payable 
0
0
0
0
0
0
787,040
418,240
422,453
377,008
239,043
286,102
395,586
125,414
106,916
124,049
284,607
284,607124,049106,916125,414395,586286,102239,043377,008422,453418,240787,040000000
       Other Current Liabilities 
276,279
143,631
141,750
111,212
275,674
1,227,422
63,195
83,314
118,277
120,363
141,945
57,626
58,774
45,582
21,497
21,491
21,200
21,20021,49121,49745,58258,77457,626141,945120,363118,27783,31463,1951,227,422275,674111,212141,750143,631276,279
   > Long-term Liabilities 
172,419
249,092
251,308
320,022
538,651
315,806
322,717
306,473
160,303
399,082
547,245
413,132
297,991
30,176
53,861
109,743
96,523
96,523109,74353,86130,176297,991413,132547,245399,082160,303306,473322,717315,806538,651320,022251,308249,092172,419
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
157,136
180,638
68,109
0
1,000
10,655
0
010,6551,000068,109180,638157,1360000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
5,782
5,316
9,950
0
0
0
0
00009,9505,3165,7820000000000
> Total Stockholder Equity
91,390
118,549
385,233
410,046
541,888
638,167
674,530
688,566
717,789
577,520
426,652
379,287
190,582
511,147
567,711
628,803
734,546
734,546628,803567,711511,147190,582379,287426,652577,520717,789688,566674,530638,167541,888410,046385,233118,54991,390
   Common Stock
66,345
95,811
159,813
159,813
174,813
183,813
186,563
186,563
186,563
186,563
186,563
236,563
236,563
23,656
236,563
236,563
236,563
236,563236,563236,56323,656236,563236,563186,563186,563186,563186,563186,563183,813174,813159,813159,81395,81166,345
   Retained Earnings Total Equity00000000000000000
   Accumulated Other Comprehensive Income 
-17,364
-20,821
-34,536
-51,915
-74,574
-98,771
-129,906
-160,859
-226,991
-269,609
-306,855
-348,771
-430,515
-391,214
289,049
289,049
289,049
289,049289,049289,049-391,214-430,515-348,771-306,855-269,609-226,991-160,859-129,906-98,771-74,574-51,915-34,536-20,821-17,364
   Capital Surplus 00000000000000000
   Treasury Stock00000000000000000
   Other Stockholders Equity 
42,409
43,559
259,956
302,148
441,648
553,124
501,006
533,295
593,319
648,153
725,399
837,315
919,059
727,031
753,765
763,346
753,765
753,765763,346753,765727,031919,059837,315725,399648,153593,319533,295501,006553,124441,648302,148259,95643,55942,409



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue1,153,499
Cost of Revenue-765,940
Gross Profit387,559387,559
 
Operating Income (+$)
Gross Profit387,559
Operating Expense-283,747
Operating Income117,723103,812
 
Operating Expense (+$)
Research Development7,212
Selling General Administrative14,803
Selling And Marketing Expenses5,625
Operating Expense283,74727,640
 
Net Interest Income (+$)
Interest Income445
Interest Expense-20,376
Other Finance Cost-445
Net Interest Income-20,376
 
Pretax Income (+$)
Operating Income117,723
Net Interest Income-20,376
Other Non-Operating Income Expenses0
Income Before Tax (EBT)116,163119,283
EBIT - interestExpense = 116,163
116,163
133,756
Interest Expense20,376
Earnings Before Interest and Taxes (EBIT)136,539136,539
Earnings Before Interest and Taxes (EBITDA)189,883
 
After tax Income (+$)
Income Before Tax116,163
Tax Provision-2,783
Net Income From Continuing Ops113,380113,380
Net Income113,380
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses1,049,687
Total Other Income/Expenses Net-1,56020,376
 

Technical Analysis of Bafna Pharmaceuticals Limited
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Bafna Pharmaceuticals Limited. The general trend of Bafna Pharmaceuticals Limited is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Bafna Pharmaceuticals Limited's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Bafna Pharmaceuticals Limited.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 92.00 < 92.00 < 92.70.

The bearish price targets are: 75.90.

Tweet this
Bafna Pharmaceuticals Limited Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Bafna Pharmaceuticals Limited. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Bafna Pharmaceuticals Limited Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Bafna Pharmaceuticals Limited. The current macd is 0.15987582.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Bafna Pharmaceuticals Limited price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Bafna Pharmaceuticals Limited. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Bafna Pharmaceuticals Limited price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Bafna Pharmaceuticals Limited Daily Moving Average Convergence/Divergence (MACD) ChartBafna Pharmaceuticals Limited Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Bafna Pharmaceuticals Limited. The current adx is 14.74.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Bafna Pharmaceuticals Limited shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Bafna Pharmaceuticals Limited Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Bafna Pharmaceuticals Limited. The current sar is 92.33.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Bafna Pharmaceuticals Limited Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Bafna Pharmaceuticals Limited. The current rsi is 50.37. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Bafna Pharmaceuticals Limited Daily Relative Strength Index (RSI) ChartBafna Pharmaceuticals Limited Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Bafna Pharmaceuticals Limited. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Bafna Pharmaceuticals Limited price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Bafna Pharmaceuticals Limited Daily Stochastic Oscillator ChartBafna Pharmaceuticals Limited Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Bafna Pharmaceuticals Limited. The current cci is 29.03.

Bafna Pharmaceuticals Limited Daily Commodity Channel Index (CCI) ChartBafna Pharmaceuticals Limited Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Bafna Pharmaceuticals Limited. The current cmo is 1.74214509.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Bafna Pharmaceuticals Limited Daily Chande Momentum Oscillator (CMO) ChartBafna Pharmaceuticals Limited Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Bafna Pharmaceuticals Limited. The current willr is -65.60846561.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Bafna Pharmaceuticals Limited is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Bafna Pharmaceuticals Limited Daily Williams %R ChartBafna Pharmaceuticals Limited Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Bafna Pharmaceuticals Limited.

Bafna Pharmaceuticals Limited Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Bafna Pharmaceuticals Limited. The current atr is 3.58465744.

Bafna Pharmaceuticals Limited Daily Average True Range (ATR) ChartBafna Pharmaceuticals Limited Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Bafna Pharmaceuticals Limited. The current obv is 143,026.

Bafna Pharmaceuticals Limited Daily On-Balance Volume (OBV) ChartBafna Pharmaceuticals Limited Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Bafna Pharmaceuticals Limited. The current mfi is 55.58.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Bafna Pharmaceuticals Limited Daily Money Flow Index (MFI) ChartBafna Pharmaceuticals Limited Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Bafna Pharmaceuticals Limited.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-19ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-02CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-08MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-27RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-29RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-21RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-01RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-04BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-24CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Bafna Pharmaceuticals Limited Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Bafna Pharmaceuticals Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.370
Ma 20Greater thanMa 5085.478
Ma 50Greater thanMa 10086.901
Ma 100Greater thanMa 20092.595
OpenGreater thanClose88.850
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Bafna Pharmaceuticals Limited with someone you think should read this too:
  • Are you bullish or bearish on Bafna Pharmaceuticals Limited? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Bafna Pharmaceuticals Limited? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Bafna Pharmaceuticals Limited

I send you an email if I find something interesting about Bafna Pharmaceuticals Limited.


Comments

How you think about this?

Leave a comment

Stay informed about Bafna Pharmaceuticals Limited.

Receive notifications about Bafna Pharmaceuticals Limited in your mailbox!